TY  - JOUR
T1  - The challenge of relapsed/refractory myeloma: An emerging role of bortezomib
A1  - Bhargav Vyasa
A1  - Arun Maseeh
JF  - Clinical Cancer Investigation Journal
JO  - Clin Cancer Investig J
SN  - 2278-0513
Y1  - 2012
VL  - 1
IS  - 4
DO  - 10.4103/2278-0513.106247
SP  - 190
EP  - 195
N2  - The treatment of multiple myeloma (MM) has undergone significant developments in recent years. The availability of the novel agents includes thalidomide and its analogs, proteasome inhibitors, arsenic trioxide, farnesyltransferase inhibitors 2-methoxyestradiol and lenalidomide has extended treatment options and has improved the outcome and quality of life of patients with MM. This review presents the totality of evidence through a systematic review that assessed the efficacy, safety or toxicity of bortezomib in patients with relapsed/refractory myeloma with or without concomitant complications. This review has precisely covered the role of bortezomib in patients with relapsed/refractory myeloma and not the newly detected populace.
UR  - https://ccij-online.org/article/the-challenge-of-relapsed-refractory-myeloma:-an-emerging-role-of-bortezomib-51
ER  -